PCR Tricuspid Focus Group
Discover an overview of the new initiative’s mission and five ongoing working groups
Interventional cardiovascular medicine is constantly evolving. Since 1989, PCR has been serving the needs of individual patients by enabling the cardiovascular community to share knowledge, skills, and experience, through life-long learning and independent medical education relevant to daily practice and always on the cutting edge of innovation.
The mission of the PCR Tricuspid Focus Group is to facilitate innovation and the development of up-to-date clinical care for patients with tricuspid valve disease. Aligning knowledge, unifying practice and eliminating cultural barriers among physicians and associations constitute the main goals of the Group.
Supporting innovation in the treatment of tricuspid valve disease
As tricuspid interventions become a clinical reality, with several thousands of patients treated per year worldwide, PCR is delighted to present the recently formed PCR Tricuspid Focus Group. This Group is committed to fostering the establishment of tricuspid therapies, improving outcomes, and delivering sustainable clinical solutions for patients with tricuspid valve disease.
Presenting the five dedicated Working Groups
In order to effectively coordinate, aggregate and harmonise their actions, the PCR Tricuspid Focus Group has formed five Working Groups of multidisciplinary Heart Team practitioners (general and interventional cardiologists, cardiac surgeons, interventional imagers, heart failure specialists, innovators, and allied health professionals).
Each team will be working towards an alignment on the following topics and messages:
- Anatomy, nomenclature, and etiology of tricuspid valve disease
- Definition of severity of disease
- Interventional imaging
- Pre-procedural optimisation
- Procedure and device selection
- Definition of procedural success
- Characterisation of the natural history of tricuspid valve disease
- Definition of endpoints for studies investigating tricuspid valve disease
- Improvement of the quality of registries in Europe
- Definition and structure of patient care pathway of patients with TR
- Definition of dedicated heart valve centers with expertise in tricuspid valve disease
- Post-procedural medical therapy and management
- Identification of the unmet clinical need in tricuspid that innovation needs to address
- Device and Imaging Innovation – Knowing existing technologies leads to Future Innovation
- Technology Innovation: Harnessing technology in innovative ways
Introducing the team behind this new initiative
Alongside PCR Chairman William Wijns, the Interventional Cardiologists Francesco Maisano and Fabien Praz have gathered a highly motivated team of approximately 90 healthcare practitioners whose enthusiastic and valuable contributions to optimise patient care deserve the community’s recognition.
Delivering independent post-graduate medical education
The PCR Tricuspid Focus Group is proud to enjoy full independence for its research and development activities, thanks to unrestricted grants from the industry partners Abbott Structural Heart as Founding Partner, Edwards, GE Healthcare, Johnson & Johnson MedTech, Medtronic, P&F, Philips and Siemens Healthineers.
Webinars - watch on replay
A year after the creation of the PCR Tricuspid Focus Group, a new series of webinars is born out of a collaboration with 4 widely known and respected associations in different specialties of cardiology: the European Heart Rhythm Association (EHRA), the European Association of Cardiovascular Imaging (EACVI), and the Heart Failure Association (HFA) of the ESC, along with the European Association for Cardio-Thoracic Surgery (EACTS).
Sincere thanks and recognition to the Industry Partners for their valuable support:
